Frank Podlaski

8.8k total citations · 3 hit papers
26 papers, 7.2k citations indexed

About

Frank Podlaski is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Frank Podlaski has authored 26 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 11 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Frank Podlaski's work include Immune Cell Function and Interaction (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Frank Podlaski is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Frank Podlaski collaborates with scholars based in United States, Switzerland and Germany. Frank Podlaski's co-authors include Daisy Carvajal, Lyubomir T. Vassilev, Zoran Filipovic, Bradford Graves, Binh Thanh Vu, Nader Fotouhi, Norman Kong, Emily A. Liu, Christian Klein and Christine Lukacs and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Frank Podlaski

26 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

2004 3.7k citations Lyubomir T. Vassilev, Binh Thanh Vu et al. Science profile →
Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

1990 579 citations A S Stern, Frank Podlaski et al. Proceedings of the National Academy of Sciences profile →
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

2013 447 citations Qingjie Ding, Zhuming Zhang et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Frank Podlaski

Since Specialization

Citations

This map shows the geographic impact of Frank Podlaski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Podlaski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Podlaski more than expected).

Fields of papers citing papers by Frank Podlaski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Podlaski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Podlaski. The network helps show where Frank Podlaski may publish in the future.

Co-authorship network of co-authors of Frank Podlaski

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Podlaski. A scholar is included among the top collaborators of Frank Podlaski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Podlaski. Frank Podlaski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Peptide Nucleic Acids Containing Cationic/Amino-Alkyl Modified Bases Promote Enhanced Hybridization Kinetics and Thermodynamics with Single-Strand DNA 2023 ·ACS Omega ·Frank Podlaski, (unknown), Kenny K. Wong, Brian A. McKittrick, Jae‐Hun Kim, (unknown), (unknown), (unknown), Peter Tolias, William T. Windsor	8
2	MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models 2013 ·Cancer Research ·Christian Tovar, Bradford Graves, Kathryn Packman, Zoran Filipovic, (unknown), (unknown), Rosario Garrido, (unknown), Kenneth Kolinsky, Kwong-Him To, (unknown), Frank Podlaski, Peter M. Wovkulich, Binh Thanh Vu, Lyubomir T. Vassilev	220
3	Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development breakdown → 2013 ·Journal of Medicinal Chemistry ·Qingjie Ding, Zhuming Zhang, Jinjun Liu, Nan Jiang, Jing Zhang, Tina Morgan Ross, Xin‐Jie Chu, David Bartkovitz, Frank Podlaski, Cheryl A. Janson, Christian Tovar, Zoran Filipovic, Brian Higgins, Kelli Glenn, Kathryn Packman, Lyubomir T. Vassilev, Bradford Graves	447
4	Biosensor-based small molecule fragment screening with biolayer interferometry 2011 ·Journal of Computer-Aided Molecular Design ·Charles Wartchow, Frank Podlaski, Shirley Xin Li, Karen Rowan, Xiaolei Zhang, Mark David, Kuo‐Sen Huang	107
5	Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy 2009 ·Cancer Research ·Sherif Daouti, Huisheng Wang, Wenhui Li, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, (unknown), Norman Kong, Nicholas Huby, Wen Yang, Qing Xiang, Frank Podlaski, Yang He, Nader Fotouhi, David Heimbrook, Huifeng Niu	25
6	NMR structure of a complex between MDM2 and a small molecule inhibitor 2004 ·Journal of Biomolecular NMR ·David C. Fry, S. Donald Emerson, Stefan Palme, Binh Thanh Vu, (unknown), Frank Podlaski	63
7	In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 breakdown → 2004 ·Science ·Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves, Daisy Carvajal, Frank Podlaski, Zoran Filipovic, Norman Kong, U. Kammlott, Christine Lukacs, Christian Klein, Nader Fotouhi, Emily A. Liu	3722
8	Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase 2003 ·Biochemical Journal ·Kui Xu, Charles Belunis, Wei Chu, David V. Weber, Frank Podlaski, Kuo‐Sen Huang, Steven I. Reed, Lyubomir T. Vassilev	28
9	Site-Specific Immobilization of Antibodies to Protein G-Derivatized Solid Supports 2000 ·Methods in molecular biology ·Frank Podlaski, A S Stern	3
10	Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits 1999 ·European Journal of Immunology ·Xin Wang, Victoria L. Wilkinson, Frank Podlaski, Changyou Wu, A S Stern, David H. Presky, Jeanne Magram	48
11	Interleukin‐12 Antagonist Activity of Mouse Interleukin‐12 p40 Homodimer in Vitro and in Vivo 1996 ·Annals of the New York Academy of Sciences ·Maurice K. Gately, Daisy Carvajal, Suzanne E. Connaughton, Silke Gillessen, Rajeev R. Warrier, Kenneth Kolinsky, Victoria L. Wilkinson, (unknown), (unknown), Frank Podlaski, D A Faherty, Philip C. Familletti, A S Stern, David H. Presky	118
12	Administration of IL-12 during ongoing immune responses fails to permanently suppress and can even enhance the synthesis of antigen-specific IgE 1995 ·International Immunology ·Tieno Germann, (unknown), Martina Bongartz, Henryka Długońska, Edgar Schmitt, Ludger Kolbe, E. Kölsch, Frank Podlaski, Maurice K. Gately, Erwin Rüde, Thomas Hünig	44
13	Interleukin‐12 profoundly up‐regulates the synthesis of antigen‐specific complement‐fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo 1995 ·European Journal of Immunology ·Tieno Germann, Martina Bongartz, Henryka Długońska, Henry Hess, Edgar Schmitt, Ludger Kolbe, Eckehart Kölsch, Frank Podlaski, Maurice K. Gately, Erwin Rüde	299
14	Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist 1995 ·European Journal of Immunology ·Silke Gillessen, Daisy Carvajal, Ping Ling, Frank Podlaski, (unknown), Philip C. Familletti, Ueli Gubler, David H. Presky, A S Stern, Maurice K. Gately	391
15	Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. 1995 ·Proceedings of the National Academy of Sciences ·Tieno Germann, Jacek Szeliga, Harald F. Hess, Stefan Störkel, Frank Podlaski, Maurice K. Gately, Edgar Schmitt, Erwin Rüde	179
16	Interleukin 12 exerts a differential effect on the maturation of neonatal and adult human CD45R0- CD4 T cells. 1994 ·Journal of Clinical Investigation ·U. Shu, Christian E. Demeure, Dae‐Gyoo Byun, Frank Podlaski, A S Stern, G Delespesse	39
17	In vitro maturation of human neonatal CD4 T lymphocytes. I. Induction of IL-4-producing cells after long-term culture in the presence of IL-4 plus either IL-2 or IL-12. 1994 ·The Journal of Immunology ·(unknown), Christian E. Demeure, Maurice K. Gately, Frank Podlaski, Hans Yssel, Mamoru Kiniwa, G Delespesse	66
18	Molecular characterization of interleukin 12 1992 ·Archives of Biochemistry and Biophysics ·Frank Podlaski, Venkata Nanduri, Jeffrey D. Hulmes, Yu‐Ching E. Pan, Wayne Levin, Waleed Danho, R Chizzonite, Maurice K. Gately, (unknown)	90
19	IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts 1991 ·The Journal of Immunology ·R Chizzonite, Theresa Truitt, Frank Podlaski, A G Wolitzky, P M Quinn, Perla Nunes, A S Stern, Maurice K. Gately	95
20	Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction. 1987 ·Journal of Biological Chemistry ·J Hakimi, C Seals, (unknown), Frank Podlaski, (unknown), Waleed Danho, James C. Jenson, Anthony V. Perkins, (unknown), P C Familletti	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact